CN103339131B - 含有吡啶酮衍生物的药物组合物 - Google Patents
含有吡啶酮衍生物的药物组合物 Download PDFInfo
- Publication number
- CN103339131B CN103339131B CN201280006755.1A CN201280006755A CN103339131B CN 103339131 B CN103339131 B CN 103339131B CN 201280006755 A CN201280006755 A CN 201280006755A CN 103339131 B CN103339131 B CN 103339131B
- Authority
- CN
- China
- Prior art keywords
- oxo
- azabicyclo
- pyridinecarboxamide
- oct
- thiazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 **(C=C(C=C1)C(*C2C(CC3)CC*3C2)=O)I1=O Chemical compound **(C=C(C=C1)C(*C2C(CC3)CC*3C2)=O)I1=O 0.000 description 1
- FVUTUSBSWIQIBT-UHFFFAOYSA-N CC(C)(C)c1cnc(N(C=C(C=C2)C(NC3C(CC4)CCN4C3)=O)C2=O)[s]1 Chemical compound CC(C)(C)c1cnc(N(C=C(C=C2)C(NC3C(CC4)CCN4C3)=O)C2=O)[s]1 FVUTUSBSWIQIBT-UHFFFAOYSA-N 0.000 description 1
- ZFIPHAMLQYAMKC-UHFFFAOYSA-N CC(C)c1cnc(N(C(C=C2)O)C=C2C(NC2C(CC3)CCN3C2)=O)[s]1 Chemical compound CC(C)c1cnc(N(C(C=C2)O)C=C2C(NC2C(CC3)CCN3C2)=O)[s]1 ZFIPHAMLQYAMKC-UHFFFAOYSA-N 0.000 description 1
- DFCXPRJJRVMTJI-UHFFFAOYSA-N CC(C)c1cnc(N(CC(C=C2)C(NC3C(CC4)CCN4C3)=O)C2=O)[s]1 Chemical compound CC(C)c1cnc(N(CC(C=C2)C(NC3C(CC4)CCN4C3)=O)C2=O)[s]1 DFCXPRJJRVMTJI-UHFFFAOYSA-N 0.000 description 1
- KQPOPTILZWOQQN-UHFFFAOYSA-N Cc1cnc(N(C(C=C2)O)C=C2C(NC2C(CC3)CCN3C2)=O)[s]1 Chemical compound Cc1cnc(N(C(C=C2)O)C=C2C(NC2C(CC3)CCN3C2)=O)[s]1 KQPOPTILZWOQQN-UHFFFAOYSA-N 0.000 description 1
- SLEJRNLGMAVMAO-UHFFFAOYSA-N O=C(C(C=C1)=CN(c(nc2)ccc2Cl)C1=O)NC1C(CC2)CCN2C1 Chemical compound O=C(C(C=C1)=CN(c(nc2)ccc2Cl)C1=O)NC1C(CC2)CCN2C1 SLEJRNLGMAVMAO-UHFFFAOYSA-N 0.000 description 1
- DYGQNPQYSHZICJ-UHFFFAOYSA-N O=C(C(C=C1)=CN(c2cnccc2)C1=O)NC1C(CC2)CCN2C1 Chemical compound O=C(C(C=C1)=CN(c2cnccc2)C1=O)NC1C(CC2)CCN2C1 DYGQNPQYSHZICJ-UHFFFAOYSA-N 0.000 description 1
- FLOPHNBQVMSNGI-UHFFFAOYSA-N O=C(C(C=C1)=CN(c2n[o]cc2)C1=O)NC1C(CC2)CCN2C1 Chemical compound O=C(C(C=C1)=CN(c2n[o]cc2)C1=O)NC1C(CC2)CCN2C1 FLOPHNBQVMSNGI-UHFFFAOYSA-N 0.000 description 1
- VQRZHJLNDICSPM-ZDUSSCGKSA-N O=C(C(C=C1)=CN(c2ncc[s]2)C1=O)N[C@@H]1C(CC2)CCN2C1 Chemical compound O=C(C(C=C1)=CN(c2ncc[s]2)C1=O)N[C@@H]1C(CC2)CCN2C1 VQRZHJLNDICSPM-ZDUSSCGKSA-N 0.000 description 1
- XDILPMLAOACYSS-UHFFFAOYSA-N O=C(C(C=C1)=CN(c2nnc(-c3ccccc3)[s]2)C1=O)NCC1C(CC2)CCN2C1 Chemical compound O=C(C(C=C1)=CN(c2nnc(-c3ccccc3)[s]2)C1=O)NCC1C(CC2)CCN2C1 XDILPMLAOACYSS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0008962 | 2011-01-28 | ||
| KR20110008962 | 2011-01-28 | ||
| PCT/KR2012/000652 WO2012102583A1 (en) | 2011-01-28 | 2012-01-30 | Pharmaceutical composition comprising pyridone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103339131A CN103339131A (zh) | 2013-10-02 |
| CN103339131B true CN103339131B (zh) | 2015-05-13 |
Family
ID=46581020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280006755.1A Active CN103339131B (zh) | 2011-01-28 | 2012-01-30 | 含有吡啶酮衍生物的药物组合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8952165B2 (https=) |
| EP (1) | EP2668185B1 (https=) |
| JP (1) | JP5859571B2 (https=) |
| KR (2) | KR101928505B1 (https=) |
| CN (1) | CN103339131B (https=) |
| AU (1) | AU2012209596B2 (https=) |
| BR (1) | BR112013018781B1 (https=) |
| CA (1) | CA2824679C (https=) |
| CL (1) | CL2013002097A1 (https=) |
| ES (1) | ES2613728T3 (https=) |
| MX (1) | MX351180B (https=) |
| PL (1) | PL2668185T3 (https=) |
| RU (1) | RU2585287C2 (https=) |
| WO (1) | WO2012102583A1 (https=) |
| ZA (1) | ZA201305227B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN109293507B (zh) * | 2018-10-12 | 2020-12-18 | 河北科技大学 | 4-甲氧基甲烯基-2-烯戊二酸二甲酯的合成方法及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1612876A (zh) * | 2002-01-07 | 2005-05-04 | 法商沙诺费-辛芷拉保公司 | 5－(吡啶－3－基)－1－氮杂二环[3.2.1]辛烷衍生物,其制备及其治疗应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404138A (en) * | 1982-06-22 | 1983-09-13 | Warner-Lambert Company | 3-[2-(Azabicyclo) ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones |
| SE0000540D0 (sv) * | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| US6492385B2 (en) * | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| NZ526580A (en) * | 2000-12-22 | 2005-04-29 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| US6569865B2 (en) * | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| AR036040A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| CA2458375A1 (en) * | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
| DE10156719A1 (de) * | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| WO2003072578A1 (en) * | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| MXPA04012439A (es) * | 2002-06-10 | 2005-04-19 | Bayer Healthcare Ag | Amidas de acidos 2-heteroarilcarboxilicos. |
| US7176198B2 (en) * | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| MXPA05003317A (es) * | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| AU2004303740A1 (en) * | 2003-12-22 | 2005-07-07 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| EP1735306A2 (en) * | 2004-03-25 | 2006-12-27 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| CA2591817A1 (en) * | 2004-12-22 | 2006-06-29 | Memory Pharmaceuticals Corporation | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
| US8106066B2 (en) * | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
| EP2344636B1 (en) * | 2008-10-09 | 2017-12-06 | Howard Hughes Medical Institute | Novel chimeric ligand-gated ion channels and methods of use thereof |
| KR101928505B1 (ko) * | 2011-01-28 | 2018-12-12 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
| KR101925971B1 (ko) * | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
-
2012
- 2012-01-27 KR KR1020120008537A patent/KR101928505B1/ko active Active
- 2012-01-30 EP EP12739548.1A patent/EP2668185B1/en active Active
- 2012-01-30 ES ES12739548.1T patent/ES2613728T3/es active Active
- 2012-01-30 MX MX2013008269A patent/MX351180B/es active IP Right Grant
- 2012-01-30 RU RU2013138218/04A patent/RU2585287C2/ru active
- 2012-01-30 CA CA2824679A patent/CA2824679C/en active Active
- 2012-01-30 US US13/980,821 patent/US8952165B2/en active Active
- 2012-01-30 PL PL12739548T patent/PL2668185T3/pl unknown
- 2012-01-30 AU AU2012209596A patent/AU2012209596B2/en active Active
- 2012-01-30 WO PCT/KR2012/000652 patent/WO2012102583A1/en not_active Ceased
- 2012-01-30 BR BR112013018781-6A patent/BR112013018781B1/pt active IP Right Grant
- 2012-01-30 JP JP2013551905A patent/JP5859571B2/ja active Active
- 2012-01-30 CN CN201280006755.1A patent/CN103339131B/zh active Active
-
2013
- 2013-07-11 ZA ZA2013/05227A patent/ZA201305227B/en unknown
- 2013-07-22 CL CL2013002097A patent/CL2013002097A1/es unknown
-
2014
- 2014-12-23 US US14/581,482 patent/US9271976B2/en active Active
-
2016
- 2016-01-18 US US14/997,754 patent/US9987259B2/en active Active
-
2018
- 2018-05-23 US US15/987,550 patent/US10456385B2/en active Active
- 2018-12-06 KR KR1020180156158A patent/KR102034305B1/ko active Active
-
2019
- 2019-09-12 US US16/568,400 patent/US20200000782A1/en not_active Abandoned
-
2020
- 2020-12-01 US US17/108,052 patent/US20210085658A1/en not_active Abandoned
-
2023
- 2023-08-21 US US18/236,001 patent/US20230390259A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1612876A (zh) * | 2002-01-07 | 2005-05-04 | 法商沙诺费-辛芷拉保公司 | 5－(吡啶－3－基)－1－氮杂二环[3.2.1]辛烷衍生物,其制备及其治疗应用 |
Non-Patent Citations (1)
| Title |
|---|
| Anilinoquinazoline Inhibitors of Fructose 1,6-Bisphosphatase Bind at a Novel Allosteric Site: Synthesis, In Vitro Characterization, and X-ray Crystallography;Stephen W. Wright,等;《J. Med. Chem.》;20020726;第45卷(第18期);3865-3877 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102034305B1 (ko) | 피리돈 유도체 및 이를 포함하는 약학적 조성물 | |
| CN103554107B (zh) | 氮杂金刚烷衍生物和应用方法 | |
| CN103328477B (zh) | 含有吡啶酮衍生物的药物组合物 | |
| NZ538058A (en) | Quinuclidine derivatives and their use for treating disorders related to CNS and PNS | |
| JP2002543201A (ja) | ヘテロアリールジアザビシクロアルカン類、その製造方法及びその使用方法 | |
| JP2002543070A (ja) | ヘテロアリールジアザシクロアルカン類、その製造方法及びその使用方法 | |
| JP5734999B2 (ja) | 神経変性および神経精神医学的障害の治療に有用な架橋アミン環縮合インドールおよびインドリン | |
| HK1187336B (en) | Pharmaceutical composition comprising pyridone derivatives | |
| CN101541792A (zh) | 氮杂金刚烷衍生物和应用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1187336 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1187336 Country of ref document: HK |